A case series showed that chimeric antigen receptor T-cell therapy targeting CD19 halted the progression of fibrotic organ ...
Researchers uncover how the skin autonomously produces antibodies through specialized immune structures, maintaining ...
Ipsen has gambled up to $610 million on a new class of bispecific T-cell engagers. The biobuck bet has landed the French ...
Hans Lee, MD, MD Anderson Cancer Center, talks about recent advancements in multiple myeloma treatment pathways.
Tomasson: Elranatamab is a bispecific antibody that binds to the BCMA on the tumor cells and the CD3-positive bone marrow ...
A news feature on the research paper “Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition” ...
In the real world, treating relapsed/refractory large B-cell lymphoma with epcoritamab and glofitamab leads to poorer ...
Ipsen secures exclusive global rights to develop, manufacture and commercialize BMX-502, a pre-clinical novel T cell engager (TCE) with ...
Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH)—a rare, aggressive ...
The selection of this first target is a key step for the partnership between Medigene and WuXi Biologics, which aims to advance multiple TCR-TCEs over the next three years. The collaboration seeks to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback